Adjuvant Treatment Approaches after Radical Prostatectomy with Lymph Node Involvement

Simple item page
dc.contributor.authorTavukçu H.H.
dc.contributor.authorErbatu O.
dc.contributor.authorAkdoğan B.
dc.contributor.authorİzol V.
dc.contributor.authorYücetaş U.
dc.contributor.authorSözen S.
dc.contributor.authorAslan G.
dc.contributor.authorŞahin B.
dc.contributor.authorTinay İ.
dc.contributor.authorMüezzinoğlu T.
dc.contributor.authorSumer
dc.date.accessioned2024-07-22T08:04:55Z
dc.date.available2024-07-22T08:04:55Z
dc.date.issued2022
dc.description.abstractObjective: The aim of this study was to evaluate the adjuvant treatment preferences and effects on disease progression in patients with pathologically positive lymph node prostate cancer. Methods: Patients who underwent radical prostatectomy from the prostate cancer database of the Turkish Urooncology Association with lymph node involvement were included in the study. Database includes prostate cancer patients from many experience Urooncology centers of Turkey. Adjuvant treatment approaches and the factors that effect the PSA recurrrence was analysed. Results: Postoperative median 2 (1-3) lymph nodes were found to be positive, and the median lymph node density was reported as 0.13 (0.07-0.25). Seventy-four percent of patients received adjuvant treatment postoperatively. Seventy four of the patients (46.54%) received hormonal therapy in combination with radiotherapy; 47 of them (29.55%) received only hormonal treatment and 20(12.57%) only received radiotherapy. The number of lymph nodes removed was less in the group requiring adjuvant treatment, and this group had a higher rate of surgical margin positivity and seminal vesicle invasion. In addition, adjuvant treatment group had a statistically significant higher lymph node density. There was no significant difference in Kaplan-Meier method comparing 5-year PSA recurrence-free survival in patients with and without adjuvant therapy. When the patient clustered as non-adjuvant, only hormonal therapy and hormonal therapy with radiotherapy, a significant survival advantage was found in the hormonal therapy with radiotherapy group compared to the other two groups (p=0.043). Conclusion: No significant difference was found between two groups in terms of time until PSA recurrence during our follow-up. In subgroup analysis survival advantage was found in the hormonal therapy with radiotherapy group compared to non-adjuvant and only hormonal therapy groups. © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.
dc.identifier.DOI-ID10.31557/APJCP.2022.23.7.2279
dc.identifier.issn15137368
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12892
dc.language.isoEnglish
dc.publisherAsian Pacific Organization for Cancer Prevention
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectChemotherapy, Adjuvant
dc.subjectHumans
dc.subjectLymph Node Excision
dc.subjectLymph Nodes
dc.subjectLymphatic Metastasis
dc.subjectMale
dc.subjectProstate-Specific Antigen
dc.subjectProstatectomy
dc.subjectProstatic Neoplasms
dc.subjectRadiotherapy, Adjuvant
dc.subjectSeminal Vesicles
dc.subjectprostate specific antigen
dc.subjectadjuvant chemotherapy
dc.subjectadjuvant radiotherapy
dc.subjecthuman
dc.subjectlymph node
dc.subjectlymph node dissection
dc.subjectlymph node metastasis
dc.subjectmale
dc.subjectpathology
dc.subjectprostate tumor
dc.subjectprostatectomy
dc.subjectseminal vesicle
dc.titleAdjuvant Treatment Approaches after Radical Prostatectomy with Lymph Node Involvement
dc.typeArticle

Files

Collections

Scopus Koleksiyonu